Shandong Hualu Pharmaceutical Co.,ltd.

Shandong Hualu Pharmaceutical Co., Ltd. is a large pharmaceutical company of the large infusion preparation production-oriented，setting research，industry and trade as one. The company currently employs more than 3,000 people, with production of fluids, water injection, capsules, tablets, granules, bulk drugs, such six formulations of over 200 specifications and varieties of drugs production capacity. The company’s production scale, technology level, and brand influence is among the forefront of the domestic industry，and  is one of the most complete variety of pharmaceutical manufacturing and packaging of the most comprehensive enterprises.

Over the years, Hua Lu, always adhering to the "carefully to make potions, and the benefit of mankind" corporate purposes, regards the quality as life, in strict accordance with the GMP requirements of production, to establish a pre-sale and after-sales service awareness, to create a good product quality Hua Lu brand, excellent visibility and reputation of corporate social climbing. The company firmly grasp the pulse of the world pharmaceutical development, make cutting-edge technology and advanced management thinking of organic integration, increase new product R & D investment, accelerate the pace of technological innovation, boldly use new technology, new facilities, to promote the pharmaceutical industry upgrading. New high-tech industrial park, with a total investment of nearly 10 billion yuan, covers an area of 800,000 square meters. The most advanced infusion production control equipment has been introduced. Through super link for full automation of the transmission system, the whole production process from raw materials into product library interlocking truly achieve full automation, the company's production capacity and efficiency to a whole new level, to build a low-cost, low power, non-polluting domestic infusion industry with international standardsgreen production demonstration garden.

In the face of intense pharmaceutical market competition, The company timely adjusts product structure, expands markets. The production of large infusion covers glass, PP plastic bottles, non-PVC multi-layer co-extrusion film soft bags and other packaging forms of transfusion products, the products involved cardiovascular drugs, antineoplastic agents, anti-infective, digestive system and prescribing medication. for research and development of Ozagrel Sodium and Sodium Chloride Injection, Tegafur and Sodium Chloride Injection，Doxofylline and Glucose Injection，Glycerol Fructose and Sodium Chloride Injection，Qianlie Antong Jiaonang，mycophenolate mofetil capsules and other competitive products in forefront of the pass and for the development of a number of strong market potential of, the market has been respected. Chinese oral preparations, mainly in the stomach complex Capsule, stomach complex piece is the development of new products and the formation of another advantage of the profit growth. With advanced production technology and reliable product quality, Hua Lu drugs has covered more than 30 provinces, municipalities and autonomous regions, and has to go abroad, exported to Southeast Asia countries and regions.

Hualu Pharmaceutical will make full use of the perfect market sales network, play in the infusion industry by a formed technical advantage, brand, product system advantage, quality advantage, the advantage of raw material supplies and powerful R & D capabilities， based on the existing production and productbasis, continue to adjust and optimize the product structure to further enhance the company's market share in the domestic infusion industry; actively look for a new scale, profit growth, and continuously enhance the competitiveness of the company, and strive to product sales revenue of 3 billion yuan in 2020, profits and taxes 450 million yuan, at the same time invest 400 million yuan to complete the construction of a number of sealed polypropylene infusion bag production line and polypropylene plastic ampoule production line, with the total assets reached 1.5 billion yuan, an annual infusion products reached 1.2 billion bottles / bags, 1.5 billion water injection , 300 million capsules production ability, and will eventually be one of the most competitive pharmaceutical manufacturers of the largest and most complete product regulation, the highest level of profitability in Chinese pharmaceutical industry,

In the coming years, Hualu Pharmaceutical will continue to be the patient's health mission, regard the quality of medicines as the vitality of enterprises, to provide consumers with better products and services. We look forward you to continue to focus on the Hualu, continue to support Hualu brand and products.
Let us work together to make new and greater contributions to the health cause of mankind!